Clinical Prevalences of Antifbrotic Therapy for ILD- A Prospective Study-

Clinical Prevalences of Antifbrotic Therapy for ILD- A Prospective Study- - Clinical Prevalences of Antifbrotic Therapy for ILD- A Prospective Study-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039664

Enrollment

250

Registered

2020-03-03

Start date

2020-03-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial Lung Disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ILD patients initiated anti fibrotic therapy or ILD patients changed anti fibrotic drugs

Exclusion criteria

Exclusion criteria: Malignancy

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS)	—

Secondary

Measure	Time frame
1) Overall Survival 2) CT finding, Symptom, Incidences of Acute Exacerbation and Lung Cancer 3) Pulmonary Function Test (%FVC) 4) Explore biomarker	—

Countries

Japan

Contacts

Public ContactYuzo Suzuki

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

yuzosuzu@hama-med.ac.jp053-435-2263

Outcome results